Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Key Highlights
- ➤Benjamin Halladay named Achieve Life Sciences (ACHV) CFO, effective October 5, 2026
- ➤Halladay joins from Esperion Therapeutics, where he served as CFO from November 2022 to July 2026
- ➤Mark Oki steps down as Achieve CFO, effective October 5, 2026
- ➤Halladay previously led finance workstream for Esperion’s sale to ARCHIMED for up to $1.1 billion
Expert Statements
Andrew D. Goldberg, Chief Executive Officer of Achieve Life Sciences
“Ben has helped scale a commercial pharma organization and expand its portfolio through business development within its existing capital structure. He has run the finance function as a public company CFO, and began his biopharma finance career in large-cap pharma. As we move toward potential commercialization of cytisinicline, that combination of capital efficiency and operating experience is exactly what this stage demands.”
Benjamin Halladay, Incoming Chief Financial Officer of Achieve Life Sciences
“The discipline that determines how a launch goes is put in place long before the first prescription is written. That is the work I’m excited to do. Achieve is developing a medicine that could change what quitting looks like for millions of people, and my job is to build the financial and operating foundation that supports it, on schedule and on plan.”
SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjamin Halladay, CPA, as Chief Financial Officer, effective October 5, 2026. He will be responsible for the Company’s financial strategy, accounting, investor relations, information technology, and other key administrative functions.
Mr. Halladay joins Achieve from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue, where he served as Chief Financial Officer from November 2022 until July 2026. During his tenure, Esperion deleveraged its balance sheet and acquired Corstasis Therapeutics and its product Enbumyst. He led the finance workstream through the company’s sale to ARCHIMED for up to $1.1 billion. As announced by Esperion, the upfront cash consideration represented a premium of 58% to its closing share price on April 30, 2026. Mr. Halladay brings more than 15 years of financial management experience across commercial and launch environments, with earlier positions at Pfizer Inc., where he worked on Lipitor and Chantix in the Primary Care business unit, and at National Oilwell Varco, a Fortune 500 global industrial company.
Get started
Create a free account to read the full story.